Serum levels of ET-1, M30, and angiopoietins-1 and -2 in HELLP syndrome and preeclampsia compared to controls.

Abstract

We aimed to compare the serum levels of ET-1, M30, and Angs-1 and -2 in patients with preeclampsia or HELLP syndrome, and normal controls. In this cross-sectional study of 74 pregnant women, serum levels of ET-1, M30, and Angs-1 and -2 were measured in preeclamptic patients with or without HELLP syndrome. 74 pregnant women; 37 had healthy pregnancies, 25 had preeclampsia (PE), and 12 had HELLP syndrome. The age, body mass index, gravidity, and parity of patients with normal pregnancy, PE, and HELLP syndrome were comparable (p>0.05). In HELLP syndrome, compared to healthy or preeclamptic pregnancies, platelet count was lower (p<0.05) and the values of hepatic function tests were higher (p<0.05). In HELLP syndrome, ET-1, M30, and Ang-2 were higher compared to healthy or preeclamptic pregnancies (p<0.05); however, they increased in preeclamptic pregnancies compared to healthy pregnancies though not significant (p>0.05). In PE or HELLP syndrome, Ang-1 was higher compared to a healthy pregnancy (p<0.05); however, in HELLP syndrome, it was also higher than in PE though not significant (p>0.05). We found no significant correlation among these biomarkers and hematological and biochemical parameters (p>0.05). For the diagnosis of HELLP syndrome, increased levels of ET-1, M30, and Angs-1 and -2 appear as promising biomarkers after determination of their standardized threshold levels after further studies. As an apoptosis-related biomarker, serum M30 level has a merit to be the most promising test for prediction or differential diagnosis of HELLP syndrome in PE patients.